Enzymatica AB (publ)

Enzymatica signs agreement for the sale of ColdZyme® at Swedish airports

Press release   •   Feb 12, 2014 11:00 GMT

The biotechnology company, Enzymatica, has signed an agreement with the pharmaceuticals wholesaler, Pharmaxim, for the distribution of ColdZyme® Mouth Spray at Swedish airports. Pharmaxim supplies all OTC medications to the Nuance Group, which is responsible for all tax-free sales of non-prescription products at Swedish airports. Pharmaxim has placed its initial order, and this has been distributed to the majority of airports in Sweden.

Air-passengers are an important target group for Enzymatica’s cold treatment spray. A US study has shown that one in five passengers catch a cold after a flight[1]. This means that both business and holiday travellers are an at-risk group simply by travelling. This also applies to all passengers using public transport. ColdZyme Mouth Spray can be used both as a preventative and as a treatment when cold symptoms have developed.

”We encourage people to use ColdZyme Mouth Spray as a preventative at an airport or during a flight. Airports and aircraft are exceptionally good environments for viruses to spread to a large number of people”, says Mats Clarsund, Head of Research at Enzymatica.

The Nuance Group has over 300 outlets in 19 countries, including tax-free stores, brand boutiques and concept stores, serving over 30 million customers every year. The Group also provides in-flight services and operates a wholesale and distribution business. Headquartered in Zurich, Nuance employs more than 5,400 people worldwide.

Pharmaxim is a Swedish wholesaler and distributor of products for human and animal health, hygiene and the environment.

”This is the company’s first agreement outside the pharmacy and health product sectors in Sweden. The agreement with Pharmaxim gives Enzymatica the opportunity to use air travel to showcase and supply ColdZyme to the international markets,” says Michael Edelborg Christensen.

For further information about Enzymatica, please contact:
Michael Edelborg Christensen, CEO, Enzymatica AB (publ), +46 (0)768-14 41 66, michael.christensen@enzymatica.se

[1] http://jama.jamanetwork.com/data/Journals/JAMA/4841/JBR20133.pdf?resultClick=1

About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

About Enzymatica online
Enzymatica’s press room »
Enzymatica’s website »
Enzymatica on LinkedIn »
Enzymatica on twitter »
For Investors »
For Investors »
ColdZyme website »
ColdZyme on facebook »